新辅助化疗在卵巢及腹膜低级别浆液性癌治疗中的作用:相对化疗耐药性的进一步证据
本研究将36例接受新辅助化疗的低级别浆液性癌(LGSC)患者与高级别浆液性癌(HGSC)患者匹配,由单一放射科医生按RECIST 1.1重新评估影像学反应。LGSC的完全细胞减灭率、CA-125下降幅度和影像学反应率均低于HGSC,中位无进展生存期18.5个月、总生存期47.4个月,进一步提示LGSC相对化疗耐药。
要点
- LGSC接受新辅助化疗后完全细胞减灭率38%,低于HGSC的75%(p=0.002)。
- LGSC影像学部分缓解仅11%,83%为疾病稳定;HGSC部分缓解75%。
- LGSC中位无进展生存期18.5个月,中位总生存期47.4个月。
核心结论
- 本研究进一步提供证据表明,接受新辅助化疗的LGSC患者相对化疗耐药。
研究设计与样本
- 将36例接受新辅助化疗的LGSC患者与HGSC患者进行匹配。
- 由单一放射科医生使用RECIST 1.1重新审阅新辅助化疗前后的影像学以评估反应。
- 采用配对t检验比较新辅助化疗前后的CA-125值,并用Kaplan-Meier法估计无进展生存期和总生存期。
主要发现
- 所有患者均接受以铂类为基础的新辅助化疗方案;LGSC患者中位5个周期(范围3-9),HGSC患者中位4个周期(范围3-9)。
- 间歇性细胞减灭术在LGSC中实施29/36(81%),在HGSC中实施32/36(89%)。
- 完全细胞减灭在LGSC中为11/29(38%),在HGSC中为24/32(75%)(p=0.002)。
- LGSC患者治疗前、后中位CA-125分别为295.5 U/mL和144 U/mL(下降52%)(p<0.001);HGSC患者分别为767.5和35.6(下降96%)(p<0.001)。
- LGSC患者中4/36(11%)达部分缓解,30/36(83%)为疾病稳定,2/36(6%)为疾病进展;HGSC患者中27/36(75%)达部分缓解,9/36(25%)为疾病稳定。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Low-grade serous carcinoma of the ovary/peritoneum (LGSC) is relatively chemoresistant in the adjuvant, neoadjuvant, and recurrent settings. We sought to expand our prior work and evaluate response rates of women with LGSC to neoadjuvant chemotherapy (NACT) compared to women with high-grade serous carcinoma of the ovary/peritoneum (HGSC). METHODS: Thirty-six patients with LGSC who received NACT were matched to patients with HGSC. A single radiologist re-reviewed pre- and post-NACT imaging for response using RECIST 1.1. Pre- and post-NACT CA-125 values were compared using paired t-tests. Kaplan-Meier estimates of progression free survival (PFS) and overall survival (OS) were performed. RESULTS: All patients received neoadjuvant platinum-based regimens. LGSC patients received a median of 5 cycles (range 3-9), HGSC patients received a median of 4 cycles (range 3-9). Interval cytoreductive surgery was performed in 29/36 (81%) of LGSC and 32/36 (89%) HGSC patients. Complete cytoreduction was reported and achieved in 11/29 (38%) of LGSC patients and 24/32 (75%) of HGSC patients (p = 0.002). Median pre- and post-treatment CA-125 levels for LGSC patients were 295.5 U/mL and 144 U/mL (52% decrease) (p < 0.001). The median pre- and post-treatment CA-125 levels for HGSC patients were 767.5 and 35.6 (96% decrease) (p < 0.001). For LGSC patients, 4/36 (11%) had partial response (PR), 30/36 (83%) had stable disease (SD), and 2/36 (6%) had progressive disease (PD). In HGSC patients, 27/36 (75%) had PR, and 9/36 (25%) SD. Median PFS for LGSC patients was 18.5 months and median OS was 47.4 months. CONCLUSIONS: This study provides further evidence of relative chemoresistance of LGSC in patients treated with NACT.
引用
- Cobb LP, Sun CC, Iyer R, et al. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. Gynecol Oncol. 2020. PMID: 32709538. doi:10.1016/j.ygyno.2020.06.498
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。